Evidence map›Paper›PMID 37310985›Full record

ArticlePloS one2023

Defining the minimum inhibitory concentration of 22 rifamycins in iron limited, physiologic medium against Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae clinical isolates.

Peggy Lu, Francesco Alletto, Bosul Lee, Elizabeth Burk, Jasmine Martinez, Fabio Prati, Emilia Caselli, Brad Spellberg, Brian Luna

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 67% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Peggy LuDepartment of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, United States of America.
Francesco AllettoDepartment of Life Science, University of Modena and Reggio Emilia, Modena, Italy.
Bosul LeeDepartment of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, United States of America.
Elizabeth BurkDepartment of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, United States of America.
Jasmine MartinezDepartment of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, United States of America.
Fabio PratiDepartment of Life Science, University of Modena and Reggio Emilia, Modena, Italy.
Emilia CaselliDepartment of Life Science, University of Modena and Reggio Emilia, Modena, Italy.ORCID 0000-0002-7248-9453
Brad SpellbergLos Angeles General Medical Center, Los Angeles, California, United States of America.
Brian LunaDepartment of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, United States of America.ORCID 0000-0001-6718-4551
Keck Hospital of USC · USUniversity of Modena and Reggio Emilia · ITLos Angeles Medical Center · US

Funding

MAb Passive Vaccination against Acinetobacter baumanniiR01AI130060 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BRAD J SPELLBERG · 2017 to 2026
$6.7M
Transferrin Combination Therapy to Address Antimicrobial ResistanceR01AI117211 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SPELLBERG, BRAD J · 2016 to 2019
$2.7M
Characterization of Rifabutin Therapy Against Antibiotic-Resistant BacteriaR01AI139052 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LUNA, BRIAN MICHAEL · 2018 to 2021
$2.4M
NIAID NIH HHS R01 AI117211NIAID NIH HHS R01 AI130060NIAID NIH HHS R01 AI139052
6 · The paper itself

Abstract

Recently, we reported rifabutin hyper-activity against Acinetobacter baumannii. We sought to characterize if any additional rifamycins (n = 22) would also display hyper-activity when tested in iron-limited media against A. baumannii, K. pneumoniae, and E. coli. MICs were determined against representative clinical isolates using the iron-limited media RPMI-1640. Only rifabutin was hyperactive against A. baumannii.

Indexed as

Acinetobacter baumanniiRifamycinsEscherichia coliIronKlebsiella pneumoniaeMicrobial Sensitivity TestsRifabutinIronRifabutinRifamycins

Identifiers

PMID37310985
PMCPMC10263351
OpenAlexW4380537290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.